Aspen fined £8m by UK competition watchdog over supply of life-saving drug

Dating service
Hand holding pharmaceuticals
The fine marks the first time a Competition and Markets Authority probe has secured payment for the NHS Credit: Kirsty O'Connor/PA

Drug firm Aspen has agreed a proposed £8m settlement with the competition watchdog following a probe into the supply of a life-saving treatment for thousands of patients on the NHS.

The Competition and Markets Authority (CMA) said Aspen had agreed the payment as part of a wider package following an investigation into suspected anti-competitive arrangements regarding the supply of fludrocortisone acetate 0.1mg tablets – a treatment for Addison's disease.

The CMA said it suspected competition law had been broken by Aspen paying two rivals to stay out of the market.

These arrangements left Aspen as the sole supplier of fludrocortisone to the NHS, with the ability to set prices without facing any...

To continue reading this article

Start a 30-day free trial for unlimited access to Premium articles

  • Unlimited access to Premium articles 
  • Subscriber-only events and experiences
  • Cancel any time

Free for 30 days

then only £2 per week

Save 25% with an annual subscription

Just £75 per year


Register for free and access one Premium article per week

Only subscribers have unlimited access to Premium articles.
Register for free to continue reading this article
Or unlock all Premium articles.
Free for 30 days, then just £1 per week